



Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1626

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/666,481
		Filing Date	September 20, 2000
		First Named Inventor	Masayuki MORITA et al.
		Group Art Unit	1626
		Examiner Name	Laura L. Stockton, Ph.D
Total Number of Pages in This Submission		Attorney Docket Number	740250-821

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Other
Remarks <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 for the above identified docket number.		

RECEIVED  
JAN 03 2003  
TECH CENTER 1600/2900

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Donald R. Studebaker, Reg. No. 32,815 Nixon Peabody LLP 8180 Greensboro Drive Suite 800 McLean, VA 22102
Signature	
Date	December 23, 2002

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Type or printed name

Signature


Date December 23, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



1-15-03  
NW  
PATENT  
740254821  
JAN 03 2003  
TECH CENTER 1600/2900  
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of ) Art Unit: 1626  
Masayuki MORITA et al. ) Examiner: Laura L. Stockton, Ph.D  
Serial No. 09/666,481 )  
Filed: September 20, 2000 )  
For: METHOD FOR PRODUCING )  
2-ALKYL-4-ISOTHIAZOLINE-3 )  
ONE )  
) CERTIFICATE OF MAILING  
I hereby certify that this correspondence is being deposited  
with the United States Postal Service with sufficient postage  
as First Class Mail in an envelope addressed to: Assistant  
Commissioner for Patents, Washington, D.C. 20231, on  
December 30, 2002.  


AMENDMENT

Honorable Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated September 30, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims 13 and 20 to read as follows:

13. (Amended) A method of producing 2-alkyl-4-isothiazoline-3-one stated in claim 1 in which aforementioned solvent is inert to the compounds of formula (I), formula (II), formula (III), and to the chlorinating agent, and in which the solubility of hydrogen chloride at normal temperature/pressure is less than 0.04 in molar fraction.